Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: Current issues and future directions
- 1 March 2004
- journal article
- review article
- Published by Wiley in Diagnostic Cytopathology
- Vol. 30 (3), 158-165
- https://doi.org/10.1002/dc.20005
Abstract
Although numerous biological and molecular markers of breast cancer have been identified over the past two decades, traditional factors such as estrogen receptor (ER), progesterone receptor (PR), and HER‐2 remain among the most useful indicators of prognosis and therapeutic response to treatment. These markers can be reliably evaluated in cytologic specimens, particularly in fine‐needle aspirates (FNA) of primary or metastatic breast cancer. Accurate assessment of ER, PR, and HER‐2 is critical in the treatment of breast cancer patients. A review of the literature, however, shows considerable interlaboratory variability in the detection of these markers and reporting of the test results. Because therapies are now being directed toward individual molecular targets, there is a need for increased standardization of such analyses. Current practices should follow consensus recommendations set by the College of American Pathologists and the American Society for Clinical Oncology, and the results should be monitored through quality‐assurance programs. The utility of cytologic specimens of breast lesions is also not limited to evaluation of individual prognostic and predictive factors. Cytologic specimens have been used successfully for genomic and proteomic studies. Such investigational studies are under way and offer great potential for revolutionizing the prediction of patient outcomes and disease response to therapy, as well as assessment of risk of developing breast cancer. Diagn. Cytopathol. 2004;30:158–165.Keywords
This publication has 46 references indexed in Scilit:
- Immunocytochemical evaluation of estrogen receptor on archival Papanicolaou‐stained fine‐needle aspirate smearsDiagnostic Cytopathology, 2003
- Current Perspectives on HER2 Testing: A Review of National Testing GuidelinesLaboratory Investigation, 2003
- Proteomic Evaluation of Archival Cytologic Material Using SELDI Affinity Mass SpectrometryAmerican Journal of Clinical Pathology, 2002
- Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinomaCancer, 2002
- HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processCancer, 2002
- Current Status of HER2 TestingAmerican Journal of Clinical Pathology, 2001
- Immunostaining of estrogen receptor, progesterone receptor, MIB1 antigen, andc-erbB-2 oncoprotein in cytologic specimens: A simplified method with formalin fixationDiagnostic Cytopathology, 1997
- Estrogen and progesterone receptors in cytology: A comprehensive reviewDiagnostic Cytopathology, 1992
- Estrogen receptors in fine-needle aspirates from metastatic lesions of gynecologic tumorsGynecologic Oncology, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987